VerbatimParliament, as it happens

Mental Illness: Drugs

Asked by Dr Al PinkertonLiberal DemocratDepartment of Health and Social CareTabled Answered 3 January 2025UIN 20768

The question

To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the potential merits of(a) the utilisation of psilocybin-based treatments for mental health conditions and (b) commissioning further research into the therapeutic applications of psychedelic drugs.

Answered by Andrew Gwynne

The Department recognises that the use of psychedelic-assisted psychotherapies, such as psilocybin, to treat mental illness is gaining attention both within the medical and scientific communities, as well as across the public more broadly. However, there is no proven medical use for psilocybin in the United Kingdom, and no such substance has yet been licensed as safe and effective in the treatment of mental health conditions. The National Institute for Health and Care Research (NIHR) is supporting psilocybin research via the NIHR King’s Clinical Research Facility, the NIHR Oxford Health Clinical Research Facility, and the NIHR Maudsley Biomedical Research Centre, where researchers are developing and evaluating the efficacy and safety of psilocybin therapies.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim